COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
ICF Inc, Fairfax, VA, USA.
Public Health Rep. 2024 Jul-Aug;139(4):501-511. doi: 10.1177/00333549231223140. Epub 2024 Feb 15.
We conducted a national US study of SARS-CoV-2 seroprevalence by Social Vulnerability Index (SVI) that included pediatric data and compared the Delta and Omicron periods during the COVID-19 pandemic. The objective of the current study was to assess the association between SVI and seroprevalence of infection-induced SARS-CoV-2 antibodies by period (Delta vs Omicron) and age group.
We used results of infection-induced SARS-CoV-2 antibody assays of clinical sera specimens (N = 406 469) from 50 US states from September 2021 through February 2022 to estimate seroprevalence overall and by county SVI tercile. Bivariate analyses and multilevel logistic regression models assessed the association of seropositivity with SVI and its themes by age group (0-17, ≥18 y) and period (Delta: September-November 2021; Omicron: December 2021-February 2022).
Aggregate infection-induced SARS-CoV-2 antibody seroprevalence increased at all 3 SVI levels; it ranged from 25.8% to 33.5% in September 2021 and from 53.1% to 63.5% in February 2022. Of the 4 SVI themes, socioeconomic status had the strongest association with seroprevalence. During the Delta period, we found significantly more infections per reported case among people living in a county with high SVI (odds ratio [OR] = 2.76; 95% CI, 2.31-3.21) than in a county with low SVI (OR = 1.65; 95% CI, 1.33-1.97); we found no significant difference during the Omicron period. Otherwise, findings were consistent across subanalyses by age group and period.
Among both children and adults, and during both the Delta and Omicron periods, counties with high SVI had significantly higher SARS-CoV-2 antibody seroprevalence than counties with low SVI did. These disparities reinforce SVI's value in identifying communities that need tailored prevention efforts during public health emergencies and resources to recover from their effects.
我们通过社会脆弱性指数(SVI)进行了一项全国性的美国 SARS-CoV-2 血清流行率研究,其中包括儿科数据,并比较了 COVID-19 大流行期间的 Delta 和奥密克戎时期。本研究的目的是评估 SVI 与感染诱导的 SARS-CoV-2 抗体血清流行率之间的关系,按时期(Delta 与奥密克戎)和年龄组进行划分。
我们使用了来自美国 50 个州的临床血清样本中感染诱导的 SARS-CoV-2 抗体检测结果(N=406469),这些样本采集于 2021 年 9 月至 2022 年 2 月之间,以估计总体血清流行率以及按县 SVI 三分位数进行划分的血清流行率。双变量分析和多层次逻辑回归模型评估了血清阳性率与 SVI 及其主题(0-17 岁,≥18 岁)和时期(Delta:2021 年 9 月至 11 月;Omicron:2021 年 12 月至 2022 年 2 月)之间的关联。
在所有 3 个 SVI 水平上,感染诱导的 SARS-CoV-2 抗体血清流行率均呈上升趋势;在 2021 年 9 月,流行率范围为 25.8%至 33.5%,在 2022 年 2 月,流行率范围为 53.1%至 63.5%。在 4 个 SVI 主题中,社会经济地位与血清流行率的关联最强。在 Delta 时期,我们发现与低 SVI 县(OR=1.65;95%CI,1.33-1.97)相比,高 SVI 县(OR=2.76;95%CI,2.31-3.21)每例报告病例的感染人数明显更多;在奥密克戎时期,我们没有发现显著差异。否则,在按年龄组和时期进行的亚组分析中,结果是一致的。
在儿童和成人中,并且在 Delta 和奥密克戎时期,高 SVI 县的 SARS-CoV-2 抗体血清流行率明显高于低 SVI 县。这些差异突显了 SVI 在确定需要在公共卫生紧急事件期间进行有针对性的预防工作以及需要从其影响中恢复的资源的社区方面的价值。